Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Golden Cross macht sich bereit: 1.350 Goldabbaustellen, 55 Ladder-Ziele und ein historischer Volltreffer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MiFDA approves Novartis' Rhapsido for CSU treatment
DiBioLineRx partners with Hemispherian to advance brain cancer therapy
MoAbbVie files NDA with FDA for tavapadon to treat Parkinson's disease
26.09.Lilly secures EC approval for Kisunla to treat Alzheimer's disease
25.09.Sandoz launches generic iron sucrose injection in US market
24.09.Leqembi approved in Australia to treat early Alzheimer's
23.09.Avenzo Therapeutics secures $60m in series B funding for oncology therapies
22.09.J&J's Tremfya gets FDA approval for SC induction in active UC
19.09.Biogen to acquire Alcyone Therapeutics for $85m
18.09.Deciphera's Romvimza secures EC nod for TGCT treatment
17.09.Dualitas secures $65m for bispecific antibody pipeline
16.09.Argo Biopharma secures NMPA clearance for Phase II PNH trial
15.09.YolTech Therapeutics raises approximately $45m via Series B financing
12.09.Dewpoint Therapeutics secures funding for DPTX3186 development
11.09.Odyssey Therapeutics raises $213m via Series D
10.09.FDA grants breakthrough therapy status to Ionis ION582 to treat Angelman syndrome
09.09.Novonesis and Novo Nordisk collaborate on gut microbiome research initiative
08.09.Takeda receives FDA approval for Vonvendi sBLA
05.09.FDA grants breakthrough therapy status to Eli Lilly's olomorasib
04.09.Andelyn and Tern partner for gene therapy to treat CLN2 Batten disease
03.09.Polpharma Biologics signs biosimilars licensing deals with MS Pharma
02.09.OMass signs deal with Genentech for IBD small molecules
01.09.FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's
29.08.EMA grants orphan designation to Aldeyra's ADX-2191 for vitreoretinal lymphoma
28.08.Leal Therapeutics raises $30m in Series A funding for neuro-metabolic therapies